Unicycive Therapeutics (UNCY) announced that it will present new oxylanthanum carbonate, OLC, data at the American Society of Nephrology, ASN, Kidney Week 2025, which will take place in Houston, TX, from November 5-9, 2025. The open-label, single-arm, multicenter, multidose study enrolled 86 CKD patients on dialysis with mean historical serum phosphate greater than or equal to4.0 and less than or equal to7.0 mg/dL for greater than or equal to8 weeks. 72 of these patients completed the study, and 70 had pretrial phosphate binder data. After washout from their prior phosphate binder, patients received OLC 500mg three times per day, titrated to a maximum of 1000mg TID over 6 weeks, followed by a 4-week maintenance period. Pretrial phosphate binders included sevelamer carbonate, calcium acetate, ferric citrate and sucroferric oxyhydroxide. Results from the study will be shared in a poster titled “Oxylanthanum Carbonate Achieves Serum Phosphate Control with Significantly Lower Pill Burden in Dialysis Patients with Hyperphosphatemia” on Thursday, November 6.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Unicycive Therapeutics price target raised to $22 from $9 at H.C. Wainwright
- Unicycive Therapeutics Updates FDA Application for OLC
- Unicycive provides update on meeting with FDA, resubmission of NDA for OLC
- UNCY Lawsuit Alert! Class Action Lawsuit Against Unicycive Therapeutics
- Unicycive Therapeutics price target adjusted at Benchmark after reverse split